Skip to main content

Advertisement

SpringerLink
Log in

Fibroblast Growth Factor 2 Levels in Patients with Major Depressive Disorder: A Meta-analysis

  • Published:
Journal of Molecular Neuroscience Aims and scope Submit manuscript

Abstract

Fibroblast growth factor 2 (FGF2) plays an essential role in neurogenesis, oxidative stress, and emotional behavior. However, the evidence regarding the role of FGF2 in the pathophysiology of depression remains limited and inconclusive. We conducted a systematic review and meta-analysis to investigate peripheral blood FGF2 levels in patients with depression and healthy controls. The PubMed and Web of Science databases were used to identify relevant articles for systematic retrieval. Eight studies involving 310 patients with depression and 268 healthy controls were included in this meta-analysis. A random-effects meta-analysis showed no difference in peripheral blood fibroblast growth factor 2 (FGF2) levels between patients with depression and HC (Hedges’ g =  − 0.288, 95% CI =  − 0.828 to 0.253, P = 0.297), but there was heterogeneity (Q = 55.719, df = 7, I2 = 87.437, P = 0.000). Subgroup analysis showed no statistically significant differences in the blood (serum/ plasma) and assay (ELISA/ no ELISA) FGF2 levels between all patients with depression and controls; however, there was heterogeneity. The meta-regression analysis showed that age, sex, sample size, depression severity, and publication year did not affect the results. Patients with different subtypes may have mild-to-severe symptoms or a different course of the disease, affecting neurotrophic factor levels. We could not obtain sufficient data from different studies to control for variables. Although the relationship between our findings and the pathophysiology of depression and the role of FGF2 in disease development remains to be determined, FGF2 may be a potential biomarker for depression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data Availability

Data are available upon request.

References

  • Akbaba N, Annagür BB, Annagür A, Akbulut H, Akyürek F, Çelık Ç (2018) Neurotrophins and neuroinflammation in fetuses exposed to maternal depression and anxiety disorders during pregnancy: a comparative study on cord blood. Arch Womens Ment Health 21:105–111. https://doi.org/10.1007/s00737-017-0774-1

  • Assembly WH (2012) Global burden of mental disorders and the need for a comprehensive, coordinated response from health and social workers at the country level: report by the Secretariat. World Health Organization, Geneva, Switzerland

    Google Scholar 

  • Chen M, Zhang QP, Zhu JX, Cheng J, Liu Q, Xu GH, Li CF, Yi LT (2020) Involvement of FGF-2 modulation in the antidepressant-like effects of liquiritin in mice. Eur J Pharmacol 881, 173297. https://doi.org/10.1016/j.ejphar.2020.173297

  • Cheng J, Chen M, Wan HQ, Chen XQ, Li CF, Zhu JX, Liu Q, Xu GH, Yi LT (2021) Paeoniflorin exerts antidepressant-like effects through enhancing neuronal FGF-2 by microglial inactivation. J Ethnopharmacol 274:114046. https://doi.org/10.1016/j.jep.2021.114046

  • Cohen J (1992) A power primer. Psychol Bull 112:155–159. https://doi.org/10.1037//0033-2909.112.1.155

  • Duman RS, Li N (2012) A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists. Philos Trans R Soc Lond B Biol Sci 367:2475–2484. https://doi.org/10.1098/rstb.2011.0357

  • Duman RS, Monteggia LM (2006) A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59:1116–1127. https://doi.org/10.1016/j.biopsych.2006.02.013

  • Elsayed M, Banasr M, Duric V, Fournier NM, Licznerski P, Duman RS (2012) Antidepressant effects of fibroblast growth factor-2 in behavioral and cellular models of depression. Biol Psychiatry 72:258–265. https://doi.org/10.1016/j.biopsych.2012.03.003

  • Fournier NM, Duman RS (2012) Role of vascular endothelial growth factor in adult hippocampal neurogenesis: implications for the pathophysiology and treatment of depression. Behav Brain Res 227:440–449. https://doi.org/10.1016/j.bbr.2011.04.022

  • Gaarden TL, Engedal K, Benth JŠ, Larsen M, Lorentzen B, Mollnes TE, Bjølseth TM, Castellheim A (2018) Exploration of 27 plasma immune markers: a cross-sectional comparison of 64 old psychiatric inpatients having unipolar major depression and 18 non-depressed old persons. BMC Geriatr 18:149. https://doi.org/10.1186/s12877-018-0836-x

  • Gaughran F, Payne J, Sedgwick PM, Cotter D, Berry M (2006) Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder. Brain Res Bull 70:221–227. https://doi.org/10.1016/j.brainresbull.2006.04.008

  • He S, Zhang T, Hong B, Peng D, Su H, Lin Z, Fang Y, Jiang K, Liu X, Li H (2014) Decreased serum fibroblast growth factor - 2 levels in pre- and post-treatment patients with major depressive disorder. Neurosci Lett 579:168–172. https://doi.org/10.1016/j.neulet.2014.07.035

  • Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558. https://doi.org/10.1002/sim.1186

  • Hisaoka K, Tsuchioka M, Yano R, Maeda N, Kajitani N, Morioka N, Nakata Y, Takebayashi M (2011) Tricyclic antidepressant amitriptyline activates fibroblast growth factor receptor signaling in glial cells: involvement in glial cell line-derived neurotrophic factor production. J Biol Chem 286:21118–21128. https://doi.org/10.1074/jbc.M111.224683

  • Kahl KG, Bens S, Ziegler K, Rudolf S, Kordon A, Dibbelt L, Schweiger U (2009) Angiogenic factors in patients with current major depressive disorder comorbid with borderline personality disorder. Psychoneuroendocrinology 34:353–357. https://doi.org/10.1016/j.psyneuen.2008.09.016

  • Katsouri L, Ashraf A, Birch AM, Lee KK, Mirzaei N, Sastre M (2015) Systemic administration of fibroblast growth factor-2 (FGF2) reduces BACE1 expression and amyloid pathology in APP23 mice. Neurobiol Aging 36:821–831. https://doi.org/10.1016/j.neurobiolaging.2014.10.004

  • Kiraly DD, Horn SR, Van Dam NT, Costi S, Schwartz J, Kim-Schulze S, Patel M, Hodes GE, Russo SJ, Merad M, Iosifescu DV (2017) Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. Transl Psychiatry 7:e1065. https://doi.org/10.1038/tp.2017.31

  • Kraus C, Kadriu B, Lanzenberger R, Zarate Jr CA, Kasper S (2020) Prognosis and improved outcomes in major depression: a review. Focus Am Psychiatr Publ 18:220–235. https://doi.org/10.1176/appi.focus.18205

  • Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100. https://doi.org/10.1371/journal.pmed.1000100

  • Lu S, Peng H, Wang L, Vasish S, Zhang Y, Gao W, Wu W, Liao M, Wang M, Tang H, Li W (2013) Elevated specific peripheral cytokines found in major depressive disorder patients with childhood trauma exposure: a cytokine antibody array analysis. Compr Psychiatry 54:953–961. https://doi.org/10.1016/j.comppsych.2013.03.026

  • Qin XY, Cao C, Cawley NX, Liu TT, Yuan J, Loh YP, Cheng Y (2017) Decreased peripheral brain-derived neurotrophic factor levels in Alzheimer's disease: a meta-analysis study (N = 7277). Mol Psychiatry 22:312–320. https://doi.org/10.1038/mp.2016.62

  • Reuss B, von Bohlen und Halbach O (2003) Fibroblast growth factors and their receptors in the central nervous system. Cell Tissue Res 313:139–157. https://doi.org/10.1007/s00441-003-0756-7

  • Shan X, Chen J, Dai S, Wang J, Huang Z, Lv Z, Wang Q, Wu Q (2020) Cyanidin-related antidepressant-like efficacy requires PI3K/AKT/FoxG1/FGF-2 pathway modulated enhancement of neuronal differentiation and dendritic maturation. Phytomedicine 76:153269. https://doi.org/10.1016/j.phymed.2020.153269

  • Shi Y, Luan D, Song R, Zhang Z (2020) Value of peripheral neurotrophin levels for the diagnosis of depression and response to treatment: a systematic review and meta-analysis. Eur Neuropsychopharmacol 41:40–51. https://doi.org/10.1016/j.euroneuro.2020.09.633

  • Simard S, Shail P, MacGregor J, El Sayed M, Duman RS, Vaccarino FM, Salmaso N (2018) Fibroblast growth factor 2 is necessary for the antidepressant effects of fluoxetine. PLoS One 13:e0204980. https://doi.org/10.1371/journal.pone.0204980

  • Smith K (2014) Mental health: a world of depression. Nature 515:181. https://doi.org/10.1038/515180a

  • Takebayashi M, Hashimoto R, Hisaoka K, Tsuchioka M, Kunugi H (2010) Plasma levels of vascular endothelial growth factor and fibroblast growth factor 2 in patients with major depressive disorders. J Neural Transm (Vienna) 117:1119–1122. https://doi.org/10.1007/s00702-010-0452-1

  • Turner CA, Watson SJ, Akil H (2012) The fibroblast growth factor family: neuromodulation of affective behavior. Neuron 76:160–174. https://doi.org/10.1016/j.neuron.2012.08.037

  • Wagner JP, Black IB, DiCicco-Bloom E (1999) Stimulation of neonatal and adult brain neurogenesis by subcutaneous injection of basic fibroblast growth factor. J Neurosci 19:6006–6016. https://doi.org/10.1523/jneurosci.19-14-06006.1999

  • Wang L, Li XX, Chen X, Qin XY, Kardami E, Cheng Y (2018) Antidepressant-like effects of low- and high-molecular weight FGF-2 on chronic unpredictable mild stress mice. Front Mol Neurosci 11:377. https://doi.org/10.3389/fnmol.2018.00377

  • Wei Z, Li X, Li X, Liu Q, Cheng Y (2018) Oxidative stress in Parkinson's disease: a systematic review and meta-analysis. Front Mol Neurosci 11:236. https://doi.org/10.3389/fnmol.2018.00236

  • Wu CK, Tseng PT, Chen YW, Tu KY, Lin PY (2016) Significantly higher peripheral fibroblast growth factor-2 levels in patients with major depressive disorder: a preliminary meta-analysis under MOOSE guidelines. Medicine (Baltimore) 95:e4563. https://doi.org/10.1097/md.0000000000004563

  • Wu HE, Teixeira AL, Barroso L, Silva APM, de Souza Nicolau M, Ferreira JDR, Bertola L, Vieira EM, Diniz BS (2019) Epidermal growth factor and fibroblast growth factor-2 circulating levels in elderly with major depressive disorder. Psychiatry Res 272:141–143. https://doi.org/10.1016/j.psychres.2018.12.084

Download references

Funding

This study was supported by the National Natural Science Foundation of China (82174085).

Author information

Authors and Affiliations

  1. Key Laboratory of Ethnomedicine of Ministry of Education, Center On Translational Neuroscience, School of Pharmacy, Minzu University of China, Beijing, 100081, China

    Yan-Li Wang, Yang Du, Lei Chen, Qing-Shan Liu & Yong Cheng

Authors
  1. Yan-Li Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yang Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qing-Shan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yong Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Qing-Shan Liu and Yong Cheng conceived and designed the study. Yang Du and Yan-Li Wang collected the data. Lei-Chen and Yan-Li Wang analyzed and interpreted the data. Yan-Li Wang drafted.

Corresponding authors

Correspondence to Qing-Shan Liu or Yong Cheng.

Ethics declarations

Competing Interests

The authors have no relevant financial or non-financial interests to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, YL., Du, Y., Chen, L. et al. Fibroblast Growth Factor 2 Levels in Patients with Major Depressive Disorder: A Meta-analysis. J Mol Neurosci 73, 95–103 (2023). https://doi.org/10.1007/s12031-023-02101-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12031-023-02101-6

Keywords

Search

Navigation